VISEN Pharmaceuticals (HKG:2561)

Market Cap	2.50B -47.4%
Revenue (ttm)	151.34K -95.1%
Net Income	-282.01M
EPS	-2.72
Shares Out	109.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,100
Open	21.90
Previous Close	22.94
Day's Range	21.02 - 22.00
52-Week Range	21.02 - 54.00
Beta	n/a
Analysts	Buy
Price Target	51.54 (+135.34%)
Earnings Date	Jun 18, 2026

About VISEN Pharmaceuticals

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company’s lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2018
• Employees: 82
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2561

Financial Performance

In 2025, VISEN Pharmaceuticals's revenue was 136,000, a decrease of -95.10% compared to the previous year's 2.78 million. Losses were -253.42 million, 39.1% more than in 2024.

Financial numbers in CNY